- +852 4750 3485
- info@mycancerinfo.org
The immune system is constantly monitoring the body for harmful or abnormal cells. In many cases, it can detect and destroy cells before they become a serious problem. However, cancer cells can evolve sophisticated ways to avoid being found and attacked.
Some cancer cells may disguise themselves so they appear more like normal cells. Others may produce signals that suppress immune activity or create a tumor environment that makes it harder for immune cells to function properly. This means that even when the immune system is aware of the cancer, it may not be able to mount a strong enough attack.
This process is known as immune evasion, and it is now recognized as one of the key hallmarks of cancer biology.
Immunotherapy is designed to overcome the strategies cancer uses to hide from the immune system. Instead of directly targeting the tumor in the same way chemotherapy or radiation does, immunotherapy aims to reactivate, strengthen, or guide the immune response so it can attack cancer more effectively.
There are several types of immunotherapy, each working in a different way.
Checkpoint inhibitors are among the most widely used forms of immunotherapy. These drugs block proteins such as PD-1, PD-L1, or CTLA-4, which cancer cells can use to switch off immune cells.
By blocking these checkpoint signals, the immune system’s T cells are able to recognize and attack cancer cells again. Checkpoint inhibitors have shown durable responses in cancers such as melanoma and lung cancer, and they remain an important part of modern oncology treatment.
CAR-T cell therapy is a more personalized form of immunotherapy. It involves collecting a patient’s immune cells, genetically modifying them in a laboratory so they can better recognize cancer, and then returning them to the body.
This creates a highly targeted immune response that can be especially powerful in certain blood cancers. CAR-T therapy has shown strong results in selected hematologic malignancies, though it is not used for every cancer type.
Cancer vaccines and other immune-modulating approaches are designed to train or stimulate the immune system to better recognize tumor-related targets. These therapies aim to improve immune surveillance and strengthen the body’s natural ability to respond to cancer.
Although some of these approaches are still developing, they represent an important and growing area of cancer research.
The effectiveness of cancer treatment varies among each patient.
While immunotherapy has transformed care for many patients, it is not universally effective. Some patients experience lasting remission or major tumor shrinkage, while others may see little or no response.
There are several reasons for this. Treatment response can depend on factors such as:
the tumor’s mutational burden
the level of immune system activation
genetic and molecular signaling pathways
the composition of the tumor microenvironment
the presence of biomarkers such as PD-L1
In other words, cancer is biologically complex, and each tumor behaves differently. Even two patients with the same type of cancer may respond very differently to the same immunotherapy.
This is why doctors often consider biomarker testing and other molecular information before recommending treatment.
Because immunotherapy does not work the same way for every patient, personalization is becoming increasingly important. The goal is not simply to ask what treatment is available, but what treatment is most likely to work for a specific person.
This is where precision medicine plays a critical role. Precision medicine uses information about the individual biology of the cancer—such as biomarkers, mutations, or other molecular features—to help guide treatment decisions.
This approach can provide deeper insight into:
whether immunotherapy is likely to be effective
which immunotherapy strategy may be more suitable
how the cancer behaves at a molecular level
whether another treatment option may be more appropriate
Rather than relying only on trial and error, precision medicine supports more data-driven and individualized decision-making.
Today, the most important question is no longer only, “What treatment is available?”
A more meaningful question is, “What treatment is most likely to work for you?”
This shift reflects a broader change in oncology. Cancer treatment is becoming more personalized, more strategic, and more focused on understanding the unique biology of each patient and each tumor.
Immunotherapy has transformed cancer care and created new possibilities for patients across many cancer types. But its success depends on something essential: understanding the individual patient behind the disease.
Not every patient will benefit from the same immune-based strategy, and not every cancer will respond in the same way. That is why continued research, biomarker testing, and personalized treatment planning are so important.
As cancer care continues to evolve, immunotherapy remains one of the most promising advances in oncology—but its greatest strength may lie in how it can be combined with precision medicine to guide smarter, more individualized care.
At Cancer A-Z, you can request a FREE 1-on-1 discussion with our cancer professionals to gain clarity on possible treatment directions.
Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.
https://doi.org/10.1158/2159-8290.CD-21-1059
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361–1365.
https://doi.org/10.1126/science.aar6711
Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350–1355.
https://doi.org/10.1126/science.aar4060
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B. P., Simon, P., Löwer, M., … Türeci, Ö. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 547(7662), 222–226.
https://doi.org/10.1038/nature23003
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168(4), 707–723.
https://doi.org/10.1016/j.cell.2017.01.017
Precision medicine provides patients with clearer and more personalized treatment guidelines
Learn how precision medicine can help with your cancer treatment
The effectiveness of cancer treatment varies among each patient.
